Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.

Journal Article (Clinical Trial, Phase IV;Journal Article)

COMPASS study demonstrated efficacy of dual pathway inhibition with 2.5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood. In this Phase IV, prospective, open-label and randomized study, we hypothesize that treatment with rivaroxaban is associated with a reduction in platelet activation and aggregation, inflammation and coagulation markers. 30 patients will be randomly treated with aspirin (81 mg q.d.) or aspirin plus rivaroxaban (2.5 mg b.i.d.) for 12 weeks. Platelet aggregation, platelet activation and inflammation markers, thrombin generation kinetics and tissue factor-induced platelet-fibrin clot strength will be measured at baseline, and 4 and 12 weeks after randomization. Trial registration number: NCT04059679.

Full Text

Duke Authors

Cited Authors

  • Tantry, U; Cummings, C; Mackrell, P; Gonze, M; Ulloa, K; Bafford, R; Rout, A; Sukhi, A; Gurbel, P

Published Date

  • March 2020

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • 69 - 75

PubMed ID

  • 32129681

Electronic International Standard Serial Number (EISSN)

  • 1744-8298

Digital Object Identifier (DOI)

  • 10.2217/fca-2019-0091


  • eng

Conference Location

  • England